{"protocolSection":{"identificationModule":{"nctId":"NCT00848770","orgStudyIdInfo":{"id":"HCPA 07-470"},"organization":{"fullName":"Hospital de Clinicas de Porto Alegre","class":"OTHER"},"briefTitle":"Manipulation of Arterial Pressure in Acute Ischemic Stroke","officialTitle":"Manipulation of Arterial Pressure Early in Non Thrombolysed Acute Ischemic Stroke: Effects on Death and Neurological Disability","acronym":"MAPAS"},"statusModule":{"statusVerifiedDate":"2009-02","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-01"},"primaryCompletionDateStruct":{"date":"2010-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2010-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2009-02-19","studyFirstSubmitQcDate":"2009-02-19","studyFirstPostDateStruct":{"date":"2009-02-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-12-30","lastUpdatePostDateStruct":{"date":"2009-12-31","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Hospital de Clinicas de Porto Alegre","oldOrganization":"GPPG"},"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a controlled clinical trial among non thrombolysed acute ischemic stroke patients to determine the effects of three levels of arterial pressure on death and neurological disability. After the admission in the vascular unit of the Emergency Department the patients are randomized to maintain during the first 24h the Systolic Arterial Pressure in tree levels of pressure: 140 to 160 mmHg; 161 to 180 mmHg and 181 to 200 mmHg. The end point of the study is the Modified Rankin score and mortality in three month after the discharge.","detailedDescription":"To maintain the tree levels of systolic arterial pressure during de first 24h we will use one of the two strategies:1) infusion of 500 to 1000ml of saline solution and/or norepinephrine solution to increase de systolic pressure or 2) infusion of esmolol or nitroprussiate solution to decrease de pressure. Every patient will have a transcranial doppler study in the first 24h to measure the mean velocity of cerebral arteries."},"conditionsModule":{"conditions":["Stroke, Acute"],"keywords":["Stroke, Acute","Systolic Pressure of Blood"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":240,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"1, 140 to 160 mmHg","type":"ACTIVE_COMPARATOR","description":"Esmolol, NPS or NOR","interventionNames":["Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)","Drug: Esmolol, NPS or NOR","Drug: manipulation of SAP"]},{"label":"2, 161 to 180 mmHg","type":"ACTIVE_COMPARATOR","description":"Esmolol, NPS or NOR","interventionNames":["Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)","Drug: Esmolol, NPS or NOR","Drug: manipulation of SAP"]},{"label":"3, 181 to 200 mmHg","type":"ACTIVE_COMPARATOR","description":"Esmolol, NPS or NOR","interventionNames":["Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)","Drug: Esmolol, NPS or NOR","Drug: manipulation of SAP"]}],"interventions":[{"type":"DRUG","name":"Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)","description":"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).\n\nNPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.\n\nNOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.","armGroupLabels":["1, 140 to 160 mmHg","2, 161 to 180 mmHg","3, 181 to 200 mmHg"],"otherNames":["Esmolol, NPS or NOR"]},{"type":"DRUG","name":"Esmolol, NPS or NOR","description":"We use one of the three drug to manipulate the systolic arterial pressure","armGroupLabels":["1, 140 to 160 mmHg","2, 161 to 180 mmHg","3, 181 to 200 mmHg"]},{"type":"DRUG","name":"manipulation of SAP","description":"Esmolol or NPS or NOR","armGroupLabels":["1, 140 to 160 mmHg","2, 161 to 180 mmHg","3, 181 to 200 mmHg"],"otherNames":["Esmolol or NPS or NOR"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Ranking score and mortality","timeFrame":"Three month"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients 18 years or older, with the first Acute Ischemic Stroke within the first 6 hours of the symptoms and not candidate to thrombolysis\n* We will also include patients with previous Ischemic Stroke with Ranking score 0 or 1\n\nExclusion Criteria:\n\n* Improuvment of the symptoms rapidly (in the first 15 min after admission)\n* Seizures not related do the acute ischemic stroke\n* Previous ischemic stroke in the last 6 weeks and with Ranking score \\> 1\n* Haemorrhagic stroke\n* Anticoagulation\n* Hypoglycemia\n* Shock\n* Acute heart failure","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Luiz A Nasi, Physician","role":"CONTACT","phone":"55 51 9982 18 44","email":"lnasi@terra.com.br"},{"name":"Miguel Gus","role":"CONTACT","phone":"55 51 81627002","email":"mgus@mgus.com.br"}],"overallOfficials":[{"name":"Luiz A Nasi, Physician","affiliation":"Hospital de Clínicas de Porto Alegre / UFRGS","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hospital de Clínicas de Porto Alegre/ UFRGS","status":"RECRUITING","city":"Porto Alegre","state":"RS","country":"Brazil","contacts":[{"name":"L A Nasi, Doctor","role":"PRINCIPAL_INVESTIGATOR"},{"name":"M Gus, Doctor","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":-30.03306,"lon":-51.23}}]},"referencesModule":{"references":[{"pmid":"15716709","type":"RESULT","citation":"Potter J, Robinson T, Ford G, James M, Jenkins D, Mistri A, Bulpitt C, Drummond A, Jagger C, Knight J, Markus H, Beevers G, Dewey M, Lees K, Moore A, Paul S; CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design. J Hypertens. 2005 Mar;23(3):649-55. doi: 10.1097/01.hjh.0000160224.94220.e7."}],"seeAlsoLinks":[{"label":"Clinical trial of Manipulation of Arterial Pressure Early in Acute Ischemic Stroke","url":"http://clinicaltrials.gov/ct2/show/NCT00848770"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M6535","name":"Death","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M27273","name":"Systolic Murmurs","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000009638","term":"Norepinephrine"},{"id":"C000036604","term":"Esmolol"}],"ancestors":[{"id":"D000000316","term":"Adrenergic alpha-Agonists"},{"id":"D000000322","term":"Adrenergic Agonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000013566","term":"Sympathomimetics"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000014662","term":"Vasoconstrictor Agents"},{"id":"D000058671","term":"Adrenergic beta-1 Receptor Antagonists"},{"id":"D000000319","term":"Adrenergic beta-Antagonists"},{"id":"D000018674","term":"Adrenergic Antagonists"}],"browseLeaves":[{"id":"M12265","name":"Norepinephrine","asFound":"Near","relevance":"HIGH"},{"id":"M4544","name":"Benzocaine","relevance":"LOW"},{"id":"M248025","name":"Esmolol","asFound":"Senior","relevance":"HIGH"},{"id":"M20436","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3358","name":"Adrenergic alpha-Agonists","relevance":"LOW"},{"id":"M3363","name":"Adrenergic Agonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M16035","name":"Sympathomimetics","relevance":"LOW"},{"id":"M17099","name":"Vasoconstrictor Agents","relevance":"LOW"},{"id":"M28887","name":"Adrenergic beta-1 Receptor Antagonists","relevance":"LOW"},{"id":"M3361","name":"Adrenergic beta-Antagonists","relevance":"LOW"},{"id":"M20445","name":"Adrenergic Antagonists","relevance":"LOW"},{"id":"T433","name":"Tannic Acid","relevance":"LOW"}],"browseBranches":[{"abbrev":"VaCoAg","name":"Vasoconstrictor Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}